It has previously been demonstrated that the detrimental effect on the performance of a delayed nonmatch to sample (DNMS) memory task by exogenously administered cannabinoid (CB1) receptor agonist, WIN 55212-2 (WIN), is reversed by the receptor antagonist rimonabant. In addition, rimonabant administered alone elevates DNMS performance, presumably through the suppression of negative modulation by released endocannabinoids during normal task performance. Other investigations have shown that rimonabant enhances encoding of DNMS task-relevant information on a trial-by-trial, delay-dependent basis. In this study, these reciprocal pharmacological actions were completely characterized by long-term, chronic intrahippocampal infusion of both agents (WIN and rimonabant) in successive 2-week intervals. Such long-term exposure allowed extraction and confirmation of task-related firing patterns, in which rimonabant reversed the effects of CB1 agonists. This information was then utilized to artificially impose the facilitatory effects of rimonabant and to reverse the effects of WIN on DNMS performance, by delivering multichannel electrical stimulation in the same firing patterns to the same hippocampal regions. Direct comparison of normal and WIN-injected subjects, in which rimonabant injections and ensemble firing facilitated performance, verified reversal of the modulation of hippocampal memory processes by CB1 receptor agonists, including released endocannabinoids.
It has previously been demonstrated that the detrimental effect on the performance of a delayed nonmatch to sample (DNMS) memory task by exogenously administered cannabinoid (CB1) receptor agonist, WIN 55212-2 (WIN), is reversed by the receptor antagonist rimonabant. In addition, rimonabant administered alone elevates DNMS performance, presumably through the suppression of negative modulation by released endocannabinoids during normal task performance. Other investigations have shown that rimonabant enhances encoding of DNMS task-relevant information on a trial-by-trial, delay-dependent basis. In this study, these reciprocal pharmacological actions were completely characterized by long-term, chronic intrahippocampal infusion of both agents (WIN and rimonabant) in successive 2-week intervals. Such long-term exposure allowed extraction and confirmation of task-related firing patterns, in which rimonabant reversed the effects of CB1 agonists. This information was then utilized to artificially impose the facilitatory effects of rimonabant and to reverse the effects of WIN on DNMS performance, by delivering multichannel electrical stimulation in the same firing patterns to the same hippocampal regions. Direct comparison of normal and WIN-injected subjects, in which rimonabant injections and ensemble firing facilitated performance, verified reversal of the modulation of hippocampal memory processes by CB1 receptor agonists, including released endocannabinoids. 
Introduction
Endocannabinoids are released by several different neural systems to alter cell and circuit activity in different brain areas (Shen et al., 1996; Tzavara et al., 2003; Foldy et al., 2006; Janero and Makriyannis, 2009) . Continual exposure to cannabinoids (CB1) is an important factor in abuse and addiction; therefore, it is critical to know whether the effects of exogenous CB1 agonists or CB1 receptor antagonists are altered after continuous long-term exposure. It is also important to know that the effects of continued exposure are present in particular regions and not the result of changes in other brain areas. Therefore, it is important to understand how endocannabinoids that modulate behavioral performance alter neural activity related to encoding of task information (Deadwyler et al., 2007) . Several recent investigations have implicated CB1 receptors in the control of glutamatergic transmission, and have demonstrated modification of NMDA receptor function by altering the effects of MK801 on locomotor activity (Auclair et al., 2000; Bubenikova-Valesova et al., 2008; Black et al., 2009) . Other studies have demonstrated that cognitive changes produced by CB1 administered systemically, can be modified by drugs that affect other convergent neuronal systems (Borowski et al., 2005; D'Souza et al., 2005; Lundqvist, 2005; Ballmaier et al., 2007; Hajos et al., 2008) . It is for these reasons that this study was undertaken, to examine the effects of intrahippocampal infusion of CB1 receptor agonists and antagonists to determine whether acute actions subside or are enhanced by chronic exposure.
Methods

Subjects
Male Long-Evans rats (n = 32), age 4-12 months, were used as subjects. Subjects were allowed free access to food, and fluid intake was adjusted daily for maintenance at 85% of free feeding body weight. All subject care and experimental procedures, including water deprivation and surgery, conformed to Institutional Animal Care and Use Committee, National Institutes of Health, and Society for Neuroscience recommendations and Association for the Assessment and Accreditation of Laboratory Animal Care regulations for care and use of experimental subjects.
Apparatus and behavioral training
Complete details of apparatus design and behavioral training have been reported previously (Hampson and Deadwyler, 2000; Hampson, 2004, 2008) . In brief, the apparatus consisted of a Plexiglas behavioral testing chamber with two retractable levers mounted on one wall, positioned to either side of a water trough, and a nose poke device mounted in the center of the wall on the opposite side of the chamber. The testing chamber was housed inside a commercially built sound-attenuated cubicle (Industrial Acoustics Co., Bronx, New York, USA) with a video camera mounted above the testing chamber. Subjects received a portion of their daily fluid intake during behavioral testing sessions (consisting of 100-150 trials) with the remainder supplied on return to their home cage. The delayed nonmatch to sample (DNMS) task consisted of three main phases: sample, delay, and nonmatch. In the sample phase, either the left or right-positioned lever was selected at random and extended into the testing chamber (Fig. 1a ). The subject responded by pressing the extended Intrahippocampal infusion of cannabinoid receptor (CB1) agents chronically alters delayed nonmatch to sample (DNMS) performance. (a) Schematic of DNMS task. Sample phase: rats were trained to press a single lever presented at random in left or right spatial position (sample). A variable 1-30-s delay is interposed after the sample response (SR) in which subjects had to nose poke into a photocell on the opposite wall of chamber during the delay (delay, dividing line). Nonmatch phase: both levers were presented and rats were required to press lever opposite the SR to receive water reward (0.2 ml per trial). (b) Hippocampal recoding and infusion regimen. Rats implanted with bilateral recording arrays consisting of two rows of eight 25-mm wire electrodes, with one row each aimed at CA1 and CA3 cell layers in hippocampus (Deadwyler et al., 2007) . Bilateral intrahippocampal infusion cannulae consisting of 26 ga. stainless steel were targeted 0.2 mm above and lateral to the midpoint of the CA3 electrodes. At surgery, intrahippocampal cannulae were connected to Alzet 2004 (4 week) osmotic minipumps containing artificial cerebrospinal fluid (ACSF) then subjects were allowed to recover and resume testing in the DNMS task. After 16-22 days, original minipumps were removed and replaced with pumps containing either rimonabant (0.33 mg/ml, n = 5 subjects) or WIN 55212-2 (0.16 mg/ml, n = 4 subjects). Subjects resumed DNMS testing 2 days after pump exchange. All behavioral and electrophysiological data reported are for days 6-15 after minipump exchange to allow time for complete cannula flush and steady state perfusion of infused drugs. After completion of testing for the first agent, minipumps were exchanged and rimonabant subjects received WIN, and WIN subjects received rimonabant infusions; behavioral and electrophysiological data collected again for days 6-15 after the 2nd minipump exchange. Upon completion of testing, minipumps were removed and cannulae sealed. (c) DNMS performance assessed during intrahippocampal infusion of rimonabant or WIN in the same subjects. Daily sessions for all subjects (n = 9) shown by delay and drug condition were averaged over 1000 trials (10 sessions) in 5-s intervals. Mean ( ± standard error of the mean) percent of correct responses on single DNMS trials is plotted for the control (ACSF/saline), rimonabant and WIN intrahippocampal infusion periods summed across all subjects. Durations of the delays were programmed for 1-30 s, however, the nose poke requirement to terminate the delay could increase the actual delay time on a given trial, hence delays for more than 30 s are shown separately (' > 30 s' interval). *P < 0.01, **P < 0.001, significant increase or decrease in DNMS performance compared with performance in the control (ACSF/saline minipump) condition. (d) Assessment of the sequence of intrahippocampal drug infusions. DNMS performance during infusion with each drug plotted as in (c) was determined for different subjects grouped according to sequence of drug infusions, rimonabant-WIN or WIN-rimonabant. There was no significant difference in the overall effect of rimonabant or WIN as a function of which drug was administered first in the series. lever, which constituted the sample response (SR). After the SR, the lever was immediately retracted and the delay phase of the task initiated (delay phase shown in Fig. 1a ). The delay phase consisted of 1-30-s intervals with no levers extended and a cue light illuminated over the nose poke device on the opposite wall. In the delay phase, the subject was required to nose poke into a photo beam to terminate the delay phase after the interval timed out; this turned off the cue light and produced extension of both levers signaling onset of the nonmatch phase of the task (Fig. 1a) . A response on the lever opposite the position of the SR, that is, a 'nonmatch response' produced a reward consisting of a drop of water (0.04 ml) delivered to a trough located between the two levers ( Fig. 1a) . A 10-s intertrial interval preceded onset of the next trial. An incorrect response in the nonmatch phase, i.e. a response on the same lever as the SR, caused the chamber lights to be turned off for 5 s with both levers retracted, after which, the lights were reilluminated, and the next trial was initiated 5 s later. Subjects were pretrained to a criterion performance level of 90% correct on trials with delays of 1-5 s in sessions of 100-150 trials with delay durations of 1-30 s prior to initiation of experimental procedures.
Surgery
All subjects were trained to criterion performance before surgery, and retrained to the same level after recovery. Subjects were anesthetized with ketamine [100 mg/kg, intraperitoneally (i.p.)] and xylazine (10 mg/kg, i.p.) and multineuron recording arrays, each consisting of 16 25-mm wire electrodes (NBLabs, Denison, Texas, USA; Neurolinc, New York, New York, USA) aimed at the CA1 and CA3 subfields bilaterally in each hippocampus, centered at coordinates: 3.8-mm posterior to bregma (anteroposterior), 3.0 mm left or right of the midline . The longitudinal axis of the array was angled 301 from the midline, with posterior electrode sites more lateral than anterior sites, following the longitudinal axis of the hippocampus. Each 16-electrode array was lowered in 25-100-mm steps to a depth in which CA3 electrodes penetrated 3.0-4.2 mm from surface of the brain and CA1 electrodes 1.6-2.8 mm, as per precut lengths. Single neuron firing from each electrode on the array was monitored during surgery to ensure placement in appropriate hippocampal cell layers.
All subjects were additionally implanted with bilateral intracranial infusion cannulae (Micheau et al., 2004) , although only 19 received intrahippocampal drug infusion for this experiment (the others received only saline). Two intrahippocampal cannulae (stainless steel, 26-gauge, L shaped) were lowered to place the respective tip coordinates adjacent to the left and right CA3 electrodes [anteroposterior (3.8 mm), midline (3.6 mm), depth (4.0, approximately 0.2 mm above and lateral to CA3 electrode placement; Fig. 1b ], and then connected by flexible polyethylene tubing to Alzet 2004 minipumps (Durect Inc., Cupertino, California, USA) containing artificial cerebrospinal fluid/saline, placed in a cavity below the skin of the neck. After surgery, the skin was replaced and sutured tight. To replace and exchange minipumps, subjects were anesthetized, and the skin over the minipumps opened with a fresh incision. The polyethylene tubing was cut, the exhausted minipump removed and replaced with a fresh filled minipump containing a suspension of rimonabant (Sanofi-Aventis, provided by Research Triangle Institute, Cary, North Carolina, USA) or WIN 55212-2 (WIN, Tocris Inc., Ellisville, Missouri, USA). After minipump replacement, the fresh incision was sutured and treated with antibiotic.
After implantation of the array and intrahippocampal infusion cannulae, the cranium was sealed with bone wax and dental cement, and subjects were allowed to recover for at least 1 week before resumption of behavioral testing. Scalp wounds and neck incisions were treated periodically with neosporin antibiotic and a systemic injection of penicillin G (300 000 U, intramuscularly) was given to prevent infection. Subjects received buprenorphine (0.01-0.05 mg/kg, i.p.) for pain relief for 4-6 h after all cranial surgeries.
Drug preparation and administration
Rimonabant (SR141716A), WIN, URB597 (Tocris), or URB602 (Tocris) were prepared from a 20-mg/ml stock in ethanol. Rimonabant, WIN, URB597, or URB602 stock (0.5 ml) were added to 2.0 ml of a Pluronic F68 detergent (Sigma-Aldrich, St Louis, Missouri, USA) in ethanol solution (20 mg/ml), in which 2.0 ml of saline (0.9%) was slowly added. The solution was stirred rapidly and placed under a steady stream of nitrogen gas to evaporate the ethanol (approximately 10 min). This resulted in a detergent/drug suspension of 5.0 mg/ml, which was then sonicated and diluted with saline to either final (i.p.) injection concentration of 2.0 mg/ml for rimonabant or WIN, or diluted to final concentration (rimonabant, WIN, URB597, or URB602) for filling of minipumps (see below). Vehicle solutions were prepared in a similar manner, except the drug was omitted (i.e. final i.p. injection vehicle = 8 mg/ml pluronic in saline).
Five subjects were treated for 2 weeks each with WIN (1.0 mg/day) then rimonabant (2.0 mg/day). Four other subjects received the same drugs in the reverse order (rimonabant 1.0 mg/day then WIN 1.0 mg/day) for 2 weeks each. Five additional subjects received 2 weeks of URB597 (5.0 mg/day) followed by 2 weeks of URB597 plus daily i.p. injections of rimonabant (2.0 mg/kg), and a final set of five subjects received the same schedule with 2 weeks of URB602 (5 mg/day) and then 2 weeks of URB602 plus daily i.p. injections of rimonabant (2.0 mg/kg). All chronic treatments were via intrahippocampal minipump (Alzet 2004, 0.25 ml/h, maximum 28 days). Each subject received three pump changes: the initial pump was filled with saline/artificial cerebrospinal fluid (ACSF)
Cannabinoids modulate memory trial to trial Hampson et al. 337 at surgery and was maintained for 21-28 days, after which the first pump change installed the first drug treatment and delivered the drug for 15-18 days. With the exception of subjects receiving URB602, the subsequent second pump change delivered a different drug for an additional 15-18 days. A final exchange of pumps washed out remaining drug with saline/ACSF (15-28 days) and was then removed and cannula sealed to prevent infection.
An additional 13 subjects received WIN (0.4-0.8 mg/kg) by daily i.p. injection. On drug administration days, subjects were injected with 1.0 ml/kg of WIN/pluronic solution approximately 10 min before the start of the behavioral session. On vehicle injection days, the same volume (1.0 ml/kg) of pluronic vehicle was administered before the session. At least 1 day of vehicle injection was imposed between each drug-testing session.
Analyses of behavioral data
The primary behavioral performance measure was the overall mean percent of correct trials during the session and mean percent of correct trials at each delay interval (assessed in 5-s increments). Multifactor analyses of variance (ANOVAs) were used, and main effects were examined further by adjusted pair-wise linear contrasts for individual comparisons of drug effects at specific delays.
Multineuron recording technique
Extracellular action potentials and behavioral events within each DNMS trial were digitized online and time stamped for computer processing (Deadwyler and Hampson, 2004) . Single neurons were isolated and selected for analysis from each of the 32 (16 per hemisphere) different hippocampal recording electrode locations. Action potential waveforms were digitized at 40 kHz and isolated in real time by derivation of individual waveform characteristics by a Plexon Multineuron Acquisition Processor (MAP, Plexon, Inc., Dallas, Texas, USA). A limit of two separately identified neurons recorded from a single electrode location was included in ensemble analyses .
Hippocampal neuron ensembles and extraction of encoding features
Hippocampal ensembles consisted of 15-25 isolated neuronal action potentials that exhibited the same waveform and firing rate criteria over a minimum of 1000 consecutive trials (at least 10 successive behavioral testing sessions) for each subject. CA1/CA3 pyramidal neurons with mean background firing rates of 0.25-2.0 Hz were utilized in analyses. Behavioral correlates were determined for each neuron by perievent histograms computed ± 1.5 s before and after the occurrence of the SR in the sample phase of the DNMS task. Earlier investigations have shown that ensemble firing during the occurrence of the SR predicts the behavioral outcome of the task (Deadwyler et al., 1996; Deadwyler and Hampson, 1997) due to the level of encoding of the position of the lever required for retrieval and decision in the nonmatch phase of the DNMS task (Deadwyler and Hampson, 2006; Hampson et al., 2011a Hampson et al., , 2011b . Neurons were only included in the analysis if they exhibited the same identified behavioral correlate across all testing sessions.
A canonical discriminant analysis utilizing multivariate procedures (Stevens, 2002; Deadwyler and Hampson, 2008; Hampson et al., 2011b) assessed ensemble neural firing using 3.0 s ( ± 1.5 s relative to time of event occurrence in 0.25-s bins) perievent histograms of the SR and nonmatch response trial events. The canonical discriminant analysis extracted common sources of variance or discriminant functions (DFs) from a time X neuron matrix of ensemble firing rates for each (15-25 neuron) ensemble in each subject. DFs were computed by canonical correlation and eigenvector decomposition (Rao, 2002) of the ensemble firing rate matrices compiled from data collected over five previous consecutive daily DNMS sessions (at least 500 total trials). Decomposition of the covariance matrix of ensemble firing by this means extracted five significant sources of variance (DFs), each of which represented a proportion of the total variance associated with a specified behavioral event. In an earlier study , it was determined that the fifth DF (DF5) demarcated firing in left versus right SRs on correct trials; therefore, in the current application, DF5 was extracted for each ensemble and analyzed for strength of SR encoding on single trials.
CA1 multineuron stimulation parameters
A custom built 16-channel stimulator (Triangle Bio-Systems Inc., Durham, North Carolina, USA) was utilized to deliver patterns of electrical pulses bilaterally to the eight CA1 electrodes in both hippocampal arrays. The stimulator delivered digital-to-analog converted biphasic output pulses in specific patterns, simultaneously to CA1 electrodes in each array. Each output channel delivered one-half of a symmetric biphasic stimulation pulse of 1.0-ms duration to a pair of adjacent electrodes in CA1 allowing bipolar stimulation that was isolated from other electrodes on the same array. Stimulator pulses were electronically gated to produce square constant voltage outputs in the range of 0.1-15 V (20-100 mA) and interpulse intervals of 0.5 ms on a given channel. The range of parameters used on a single output channel was: biphasic, 1.0-4.0 V p-p, 1.0 ms, 10.0 Hz or more. Singlepulse stimulation intensity was adjusted to produce reliable field potentials recorded from adjacent electrodes in the array. Stimulation patterns consisted of eight channels of biphasic pulses simultaneously delivered to CA1 electrodes, in trains of 1.5-3.0-s duration that conformed to earlier analyzed firing patterns from the same electrode locations during SR occurrence. Stimulation patterns were derived from common patterns of neural firing computed ±1.5s around SR events across 13 subjects tested in this study, and 45 subjects tested under similar conditions in an earlier study (Berger et al., 2011) .
Results
Previous studies from this laboratory showed that endocannabinoids modulate task-related hippocampal encoding of information on a trial-by-trial basis in a DNMS short-term memory task (Deadwyler et al., 2007; Deadwyler and Hampson, 2008) . The same task was utilized here to examine the effects of chronic exposure to CB1 receptor agonists and antagonists, and to assess the corresponding changes in hippocampal ensemble encoding of task-specific information on a trial-by-trial basis (Hampson et al., 2011a (Hampson et al., , 2011b .
Hippocampal cannabinoid receptor modulation of delay nonmatch to sample behavior Thirty-two Long Evans rats were trained to perform a DNMS task (Fig. 1a ) to assess hippocampal encoding of short-term, working memory. Subjects were then treated with the potent CB1 agonist WIN and antagonist rimonabant to respectively suppress or enhance hippocampal encoding of DNMS events as shown in earlier reports (Hampson and Deadwyler, 2000; Hampson et al., 2003; Deadwyler and Hampson, 2008; Goonawardena et al., 2010a Goonawardena et al., , 2010b . To confirm the role of CB1 receptors confined to hippocampal CA1 and CA3 neurons, nine Long Evans rats were implanted with electrode arrays as well as bilateral infusion cannulae targeting the CA3/CA1 regions of hippocampus. Figure 1b illustrates the array/ cannula arrangement and infusion protocols used for each group of subjects. Figure 1c (Deadwyler et al., 2007) , rimonabant improved overall DNMS performance [87.5 ± 1.3%, F(1,1890) = 9.44, P < 0.001], most significantly at longer delays (Fig. 1c ).
To confirm that there was no differential effect of the sequence of intrahippocampal drug infusion, analyses of the same performance data shown in Figure 1c as a function of the order of exposure (rimonabant-WIN vs. WIN-rimonabant) is depicted in Figure 1d . There was no significant difference due to sequence of exposure for rimonabant [left graph: F(1,1890) = 1.38, not significant (NS)] or WIN [right graph: F(1,1890) = 0.97, NS].
Cannabinoid modulation of neural encoding
Earlier studies from this laboratory have demonstrated that canonical analysis yields DFs, which can be used to identify components of hippocampal ensemble activity that specifically encode spatial (lever position) and nonspatial (task phase and correct outcome) features of the DNMS task (Deadwyler et al., 1996; Deadwyler and Hampson, 1997 Hampson et al., 2003 Hampson et al., , 2011b . It has also been verified that DF5 accounted for approximately 12-15% of the overall variance in ensemble firing and discriminated left from right SRs on correct trials The reciprocal effect of CB1 receptor activation and blockade on the strength of SR encoding is shown in Figure 2a , which displays the three-dimensional temporal distribution of DF5-weighted firing for a single ensemble of 12 CA1 neurons at the SR. The spatiotemporal color contour plots indicate different ensemble encoding strengths derived by multiplying the mean firing rate of each neuron by its respective DF5 coefficient with the resultant weighted firing of ± 2.0 s relative to the occurrence of the SR (0.0 s). The increased intensity of ensemble firing (yellow-to-red shading) in the center panel of Figure 2a is evidence for increased ensemble representation (i.e. encoding) of SR information and improved DNMS performance at long delays ( Fig. 1c ) during rimonabant infusion. Decreased ensemble firing ( Fig. 2a lower) compared with both rimonabant and control conditions, likewise, confirms reduced SR encoding associated with decreased DNMS performance after chronic WIN infusion (Fig. 1c) . Figure 2b shows the distribution ensemble neuron DF5 scores (firing rate X DF5 coefficient summed over neurons and SR time frame shown in Fig. 2a (Fig. 2b, green) shows that the left and right DF5 score distributions during rimonabant infusion were skewed to the extremes and differed from control distributions as determined by w 2 population analyses [w 2 (16) = 35.7, P < 0.001]. In contrast, infusion of WIN (Fig. 2b, red) shifted DF5 scores in the opposite direction, toward zero, exhibiting a significant difference in both control [w 2 (16) = 42.8, P < 0.001] and rimonabant [w 2 (16) = 65.2, P < 0.001] distributions. Figure 2c depicts the same distributions in terms of magnitude of DF5 SR scores (absolute values) for each lever position shown in Figure 2a to illustrate on the same scale, the more 'effective' SR encoding (i.e. higher DF5 scores) during rimonabant infusion relative to control sessions and 'ineffective' encoding associated with more impaired performance ( Fig. 1c ) during WIN infusion (Fig. 2c , lower scores). Figure 2d plots the mean ( + S.E.M.) number of neurons per ensemble that showed significantly increased firing during the SR, after weighing by the coefficients of the respective DFs , to greater than two standard deviations above background firing rate (2.0-3.0 s before the SR) during control, rimonabant, and WIN infusion. Rimonabant infusion significantly increased the number of neurons contributing to both F(1,81) = 5.9, P = 0.02].
Chronic modification of endocannabinoid levels by metabolic inhibition Figure 3a shows the effects of 2-week exposure to the monoacylglycerol ( The fact that these latter agents, whose chemical action increases levels of endocannabinoids above normal levels (Karanian et al., 2005; Manwell et al., 2009) , acted specifically and consistently when administered in a chronic manner, demonstrated by the reversal with rimonabant preinjection, confirms that it was endocannabinoids that modulated DNMS performance and suppressed encoding of information in ensembles of hippocampal neurons.
Reinstatement of cannabinoid-suppressed delay nonmatch to sample performance
Although chronic infusion of WIN reduced DNMS performance in the above demonstrations, it has also been demonstrated that systemic i.p. WIN injections decrease performance in the same task (Hampson and Deadwyler, 2000; Hampson et al., 2003; Deadwyler and Hampson, 2008; Goonawardena et al., 2010a Goonawardena et al., , 2010b . To understand the relationship of the process of disruption by both CB1 agonists and endocannabinoids a unique countermeasure was applied, on a session-by-session basis, to subjects injected systemically (i.p.) with WIN. The procedure involved multichannel electrical stimulation delivered to CA1 via the same hippocampal recording arrays in a manner that mimicked the SR spatiotemporal firing pattern as illustrated in Figure 2a . Recent results have shown that DNMS performance can be enhanced under normal conditions by applying precharacterized SR patterns by means of electric pulses delivered bilaterally to the CA1 regions at the time of the SR in the same electrode array (Berger et al., 2011) . It was also reported in the same investigation that performance could be restored by application of similar electrical stimulation patterns when hippocampal neural activity was compromised through local infusion of disruptive pharmacological agents.
The above stimulation procedure was tested in this study to determine whether CA1 stimulation using 'effective' SR firing patterns similar to those produced by rimonabant (Figs 2 and 3) , were capable of restoring DNMS performance on an individual trial-by-trial basis in subjects with reduced performance by systemic (i.p.) injections of WIN. Effective CA1 firing patterns obtained from rimonabant sessions in the same subjects (Figs 2 and 3) were used to program multichannel stimulation (Hampson et al., 2011b ) delivered bilaterally to the CA1 electrodes in hippocampal arrays (Fig. 4a ). Figure 4b shows mean ( ± S.E.M.) DNMS performance summed across 13 subjects exposed to both 0.4 and 0.6 mg/kg doses of WIN (i.p.), which dose dependently decreased DNMS performance [control: 80.3 ± 0.9%, WIN 0.4 mg/kg: 67.8 ± 1.4%, WIN 0.6 mg/kg: 64.8 ± 0.9%, F(2,354) = 7.8, P < 0.001] at all delays longer than 5 s [F(1,354) = 6.9, P < 0.01, F(1,354) = 11.5, P < 0.001]. Ensemble stimulation patterns were delivered to CA1 electrodes on 30% of long-delay (> 15 s) trials during sessions in which subjects received doses of WIN (i.p.) shown to impair performance at the same delays. Figure 4b shows that performance was improved in sessions using stimulation Figure 4c shows the relative change in the DNMS performance, indicated by difference scores at all delays for (i) WIN sessions (overall mean 0.4 mg/kg: -9.7 ± 2.0% 0.6 mg/kg: -12.5 ± 1.5%) relative to control sessions (control vs. WIN) shown in Figure 4a and 4b WIN + stimulation sessions calculated as the difference from the WIN session with the same dose level (WIN + stimulation: mean % change + 8.7 ± 1.4%). Figure 4d illustrates that the latter differences in performance were due to the marked improvement on more than 15-s delay trials when effective stimulation was delivered [mean: no stimulation 60.6 ± 1.6% vs. stimulation 81.0 ± 1.1%, F(1,354) = 38.2, P < 0.001], whereas performance was suppressed on trials without stimulation (No stimulation) at the same delays.
As DNMS performance was improved on only a select number of long-delay (> 15 s) stimulation trials in WIN i.p. sessions, it reveals that CB1 receptor control of performance was through modulation of hippocampal encoding of SR lever position on a trial-to-trial basis during the session.
Discussion
The study reported here shows that CB1 receptor agonists or endocannabinoid reuptake inhibitors, continuously infused into the hippocampus over several days, chronically depress performance of a DNMS memory task. The results also show that such endocannabinoid suppression can be alleviated by subjecting the same ensembles of neurons to subsequent exposure to CB1 receptor antagonists for the same 2-week duration. Changes in the ability of hippocampal ensembles, to encode task-specific information, were assessed during each chronic exposure period and were shown to be directly related to performance efficacy. These findings provided the means to reverse the effects of systemic injections of CB1 agonists by electrically stimulating ensembles of hippocampal neurons in a manner defined by the firing patterns of the same ensemble on successful trials (Hampson et al., 2011a (Hampson et al., , 2011b . Results indicate that the detrimental effects of CB1 receptor modulation of information encoding by endocannabinoid release during performance of the DNMS task, can be overcome by delivery of task-relevant, ensemble-mimicked, electrical stimulation patterns.
The above results using long-term chronic infusion of CB1 is similar to that observed with periodic systemic injections ( Fig. 2d ). This was also significantly reversed by an earlier injection of rimonabant (green bars). *P < 0.01, **P < 0.001. Hampson and Deadwyler, 2000; Takahashi et al., 2005) . The fact that chronic intrahippocampal infusion of WIN produced consistent suppression of hippocampal ensemble encoding of task-relevant information (SR), and correspondingly depressed DNMS performance, indicates that the hippocampus is a specific target of CB1 receptor agonists and antagonists (Reibaud et al., 1999; Lichtman, 2000; Abush and Akirav, 2010) . This lack Cannabinoids modulate memory trial to trial Hampson et al. 343 of adaptation to the mnemonic detriments of CB1 receptor agonists makes it likely that earlier demonstrations of altered ensemble encoding produced by transient i.p. injections (Deadwyler et al., 2007) were the result of direct actions on hippocampal cellular and synaptic processes (Fortin et al., 2004; Foldy et al., 2006) . Figure 1 shows an important feature of the effects of CB1, namely that the chronic effects of both WIN and rimonabant did not influence DNMS performance on short-delay (1-5 s) trials, but decreased or increased performance respectively in a delay-dependent manner irrespective of which drug or the order in which it was chronically infused over a 2-week time period. Figure 2 verifies earlier reports of the modulation of hippocampal ensemble encoding during DNMS performance by CB1 receptor agonists and antagonists in the same manner as systemic i.p. administration (Heyser et al., 1993; Hampson and Deadwyler, 1998 , 2000 Hampson et al., 2003) . However, in this case both direct CB1 receptor agonists and metabolic inhibitors (Fig. 3) were chronically administered and restricted to hippocampus, and produced the same type of rimonabantsensitive impairment in performance. The fact that the magnitude of discriminant SR scores in the same chronic drug conditions were either increased or decreased, in terms of respective changes in DNMS performance, clearly implicates CB1 activation or suppression in modulating hippocampal function, as reported in several recent studies (Foldy et al., 2006; Deadwyler et al., 2007; Falenski et al., 2007; Hampson et al. 2008; Moreira et al., 2009; Abush and Akirav, 2010) . However, these results also show that chronic infusion of rimonabant alone was capable of significantly enhancing hippocampal processing in the DNMS task (Fig. 2) , which indicates that endocannabinoids modulate hippocampal activity during normal task performance, not just when agents are applied exogenously before individual sessions. Figure 2a confirms this distinction by showing that under control (nondrug) conditions, task-specific ensemble firing during the SR was midway between enhanced or suppressed levels produced by chronic intrahippocampal exposure to rimonabant or WIN, respectively. This chronic action of endcannabinoids at CB1 receptors has been verified in other studies showing facilitation of different behavioral outcomes by blockade of endocannabinoids administered acutely to produce transient beneficial effects for the duration of action of the CB1 antagonists (Gaisler-Salomon and Weiner, 2003; Gaisler-Salomon et al., 2008) . It is not obvious at this time why endocannabinoid modulation of hippocampal activity occurs under normal testing conditions; however, suppression or alteration in the patterns of ensemble firing could reflect operations that are useful under conditions in which endocannabinoid release is provoked, such as regimented exploration during searching for food .
This specificity of endocannabinoid modulation of trialby-trial DNMS performance was determined by the actions of two specific compounds, a fatty acid amide hydrolase inhibitor (URB597) and a MAG lipase inhibitor (URB602), both of which have been shown to increase levels of endocannabinoids (Karanian et al., 2005; Manwell et al., 2009) . The fact that the 'WIN-like' detrimental effects on performance were also reversed by rimonabant ( Fig. 3) provides further evidence for modulation of DNMS performance by CB1 receptors within the hippocampus. Further support for this specificity is shown by the fact that neither agent produced the same degree of disruption as WIN, a potent receptor agonist, since the only manner in which endocannabinoids could increase action was by secondary changes in levels due to inhibition of hydrolysis of anandamide (URB597), and also 2AG by MAG lipase inhibition (URB602).
The final demonstration that endocannabinoids act specifically to modulate task-dependent firing of hippocampal neurons is shown in Figure 4 , in which substitution of ensemble firing with ensemble-derived patterned electrical stimulation (Berger et al., 2011) effectively reversed the WIN-produced deficit in DNMS performance. The convergence of two independent findings in this study provides additional evidence for a common underlying cellular process modulated by endocannabinoids, capable of being reversed by different treatments (Fortin et al., 2004; Glickfeld and Scanziani, 2006) . First, chronically infused rimonabant produced enhanced performance under normal (nondrug) conditions by facilitating ensemble-firing components identified by discriminant analyses to represent trial-specific SR encoding (Figs 1  and 2) . Second, the same patterns delivered as electrical stimulation during the SR in WIN-stimulation sessions not only enhanced performance, but also reversed the effects of i.p. WIN on selective long-delay trials in a manner similar to rimonabant (Figs 1 and 4 ). Figure 4c also shows that shortdelay trials were facilitated in WIN-stimulation sessions, even though stimulation was not delivered on those trials, which is consistent with earlier findings showing that enhanced ensemble SR encoding produced by injection of rimonabant eliminated endocannabinoid-induced sequential dependent performance errors after long-delay trials .
As shown in Figure 4 , the dominant control of performance by endocannabinoid levels can be substantially altered by administering electrical stimulation in the pattern of ensemble firing during the SR (Figs 2 and 3 ). Figure 2 also shows that, for the duration of chronic intrahippocampal infusion of rimonabant, both the CB1 agonist-induced behavioral deficits and concomitant hippocampal ensemble SR encoding were reversed and elevated above normal (control) levels, which provides further evidence that the SR ensemble firing pattern was the critical factor modulated by endocannabinoids during the task (Watson and Stanton, 2009 ). This is also consistent with the recent demonstration that NMDA receptor-mediated control of intracellular calcium release can be modulated directly by endocannabinods and is facilitated by application of rimonabant in hippocampal slices (Hampson et al., 2011a) . Finally, showing 'trialspecific enhancement' of DNMS performance by delivery of effective ensemble electrical SR stimulation patterns to the same neurons disrupted by CB1 receptor activation ( Fig. 4c and d) , clearly confirms that endocannabinoids play a major role in the encoding of hippocampal memory in event-specific contexts.
